Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

March 23, 2023

https://www.globenewswire.com/news-release/2023/03/23/2633628/0/en/Erasca-Reports-Fourth-Quarter-2022-and-Full-Year-2022-Financial-Results-and-Business-Updates.html

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering

Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials for ERAS-007, ERAS-601, and ERAS-801

Read more at globenewswire.com

Related news for (ERAS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.